Liye Bsc Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Liye Bsc Fang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Adeniyi Michael Adebesin
Chemistry Division Departments of Biochemistry and Pharmacology University of Texas Southwestern Medical Center Dallas Texas USA
1 shared publication - Ahmed M. Darwesh
Faculty of Pharmacy and Pharmaceutical Sciences, 2026-M Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, AB, Canada
1 shared publication - Andy Huang
Faculty of Pharmacy and Pharmaceutical Sciences, 2026-M Katz Group Centre for Pharmacy and Health Research, University of Alberta, Edmonton, AB, Canada
1 shared publication - Jacob V. Korodimas
Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
1 shared publication - John M. Seubert
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada
1 shared publication - John Russell Falck
Departments of Biochemistry and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
1 shared publication
Latest Publications
- 1 January 2024
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 83 (1) , 105-115
Cardioprotective Action of a Novel Synthetic 19,20-EDP Analog Is Sirt Dependent
Mounting evidence suggests that CYP epoxygenase-derived metabolites of docosahexaenoic acid, called epoxydocosapentaenoic acids (EDPs), limit mitochondrial damage following cardiac injury. In particular, the 19,20-EDP regioisomer has demonstrated potent cardioprotective action. Thus, we investigated our novel synthetic 19,20-EDP analog SA-22 for protection against cardiac IR injury. Isolated C57BL/6J mouse hearts were perfused via Langendorff apparatus for 20 minutes to obtain baseline function followed by 30 minutes of global ischemia. Hearts were then treated with either vehicle, 19,20-EDP, SA-22, or SA-22 with the pan-sirtuin inhibitor nicotinamide (NAM), or the SIRT3-selective inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) at the start of 40 minutes reperfusion (N=5-8). We assessed IR injury-induced changes in recovery of myocardial function, using left ventricular developed pressure, systolic and diastolic pressure change. Tissues were assessed for ETC function, SIRT-1 and -3, optic atrophy type-1, and caspase-1. We also utilized H9c2 cells in an in vitro model of hypoxia/reoxygenation injury (N=3-6). Hearts perfused with SA-22 had significantly improved postischemic LVDP, systolic and diastolic recovery (64% of baseline), compared to vehicle control (15% of baseline). In addition, treatment with SA-22 led to better catalytic function observed in electron transport chain and SIRT enzymes. The protective action of SA-22 resulted in reduced activation of pyroptosis in both hearts or cells following injury. Interestingly, while NAM co-treatment worsened functional outcomes, cell survival and attenuated sirtuin activity, it failed to completely attenuate SA-22-induced protection against pyroptosis, possibly indicating EDPs exert cytoprotection through pleiotropic mechanisms. In short, these data demonstrate the potential of our novel synthetic 19,20-EDP analog, SA-22, against IR/HR injury and justifies further development of therapeutic agents based upon 19,20-EDP.
- 1 January 2024
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 83 (1) , 105-115
Cardioprotective Action of a Novel Synthetic 19,20-EDP Analog Is Sirt Dependent
Mounting evidence suggests that CYP epoxygenase-derived metabolites of docosahexaenoic acid, called epoxydocosapentaenoic acids (EDPs), limit mitochondrial damage following cardiac injury. In particular, the 19,20-EDP regioisomer has demonstrated potent cardioprotective action. Thus, we investigated our novel synthetic 19,20-EDP analog SA-22 for protection against cardiac IR injury. Isolated C57BL/6J mouse hearts were perfused via Langendorff apparatus for 20 minutes to obtain baseline function followed by 30 minutes of global ischemia. Hearts were then treated with either vehicle, 19,20-EDP, SA-22, or SA-22 with the pan-sirtuin inhibitor nicotinamide (NAM), or the SIRT3-selective inhibitor 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP) at the start of 40 minutes reperfusion (N=5-8). We assessed IR injury-induced changes in recovery of myocardial function, using left ventricular developed pressure, systolic and diastolic pressure change. Tissues were assessed for ETC function, SIRT-1 and -3, optic atrophy type-1, and caspase-1. We also utilized H9c2 cells in an in vitro model of hypoxia/reoxygenation injury (N=3-6). Hearts perfused with SA-22 had significantly improved postischemic LVDP, systolic and diastolic recovery (64% of baseline), compared to vehicle control (15% of baseline). In addition, treatment with SA-22 led to better catalytic function observed in electron transport chain and SIRT enzymes. The protective action of SA-22 resulted in reduced activation of pyroptosis in both hearts or cells following injury. Interestingly, while NAM co-treatment worsened functional outcomes, cell survival and attenuated sirtuin activity, it failed to completely attenuate SA-22-induced protection against pyroptosis, possibly indicating EDPs exert cytoprotection through pleiotropic mechanisms. In short, these data demonstrate the potential of our novel synthetic 19,20-EDP analog, SA-22, against IR/HR injury and justifies further development of therapeutic agents based upon 19,20-EDP.